Compare Merck & Co., Inc. (MRK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $135.74 (market cap $327.94B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.63. The key difference: Merck & Co., Inc. pays a 2.56% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | TLT | |
|---|---|---|
Market Cap | $327.94B | — |
Sector | Health | — |
52-Week High | $132.93 | $92.06 |
52-Week Low | $77.60 | $82.05 |
Enterprise Value | $374.70B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $135.55, up 3.91% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and the acquisition of Terns Pharmaceuticals bolster its oncology pipeline. The stock shows robust revenue growth and profitability, though valuation ratios like a P/E of 106.34 are elevated. Analyst consensus is strongly bullish with a $140.58 price target.
Outlook is positive driven by strategic acquisitions and earnings momentum, but risks include high valuation sensitivity and competitive pressures. The stock offers growth potential with a stable dividend, yet investors should monitor execution on integration and patent expirations for sustained upside.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.11, down 0.1% on the day, with a bearish technical signal driven by moving averages. Recent news highlights pressure from rising Treasury yields and U.S. debt nearing $40 trillion, while institutional buying by Ferguson Shapiro LLC (37,900 shares, SEC filing August 10, 2026) provides some support. Dividend payments remain consistent, with the latest at $0.34 paid on June 4, 2026.
Outlook is cautious due to macroeconomic headwinds like inflation and potential Fed rate hikes, which could push yields higher and pressure TLT's price. The ETF's large AUM of $42.5 billion offers liquidity, but investors face interest rate risk amid bearish technicals and neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
